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INTRODUCTION
Large granular lymphocytes (LGL) comprise 10% to 15% of normal peripheral blood mononuclear cells which 
morphologically are identifiable subset of peripheral blood lymphocytes. They included natural killer (NK) cells and 
cytotoxic T-cells. These cells represent in vivo antigens activated T-cells, as a response to viral or other infections. 
Clonal disorder CD3+ T-LGL represents 2-3% cases of mature lymphocytic leukaemia.[1] Typically, it is a 
heterogenous indolent disorder characterized by persistent (> 6 months) increase in the number of peripheral blood 
(PB) large granular lymphocytes usually between 2-20 x 209/L.[1, 2] In contrast, CD3- NK-cell leukaemia is an 
aggressive subtype which affect a younger group of patients. LGL NK-like leukaemia a rare described as an aggressive 
CD3+, CD56+ variant of T-LGL leukaemia is illustrated here. The literature on the clinic-pathological features and 
management approaches for this rare, aggressive entity are reviewed.
CASE REPORT
A 19-year-old Chinese, girl was referred for further investigation and management of pancytopaenia. She presented 
with history of fever, generalized malaise, loss of appetite and significant loss of weight within few months. Her 
physical examination revealed enlarged liver and massive splenomegaly with generalized lymphadenopathy. 
Her complete blood profile revealed a WBC of 1.1 x 109/L (4.0-10.0 x 109/L), haemoglobin of 6 g/dl (12.0-16.0 
g/dl) and platelet count of 40 x 109/L (150-400 x 109/L). Pertinent chemistries revealed: normal liver function test, 
LDH of 785 U/L (211-423) U/L and total bilirubin of 32 µmo/L. Her blood culture was negative. Serology studies 
showed her blood was positive for EBV IgG but negative for EBV IgM, Hepatitis C, HIV-1 and 2 and CMV IgM. Both 
rheumatoid factor (RF) and antinuclear antibody (ANA) were negative. Quantitative immunoglobulins were within 
normal limits. 
Blood film examination showed predominantly abnormal looking, large mononuclear/ lymphoid cells that constitutes 
55% of the white blood cells population. These cells were of varying sizes with abundant irregular cytoplasm, and 
some having cytoplasmic granules. Subsequent bone marrow aspirate evaluation showed hypercellular marrow with 
predominantly similar type of mononuclear/lymphoid cells (figure 1). Multiple aggregates of these mononuclear cells, 
positive for CD3 (figure 2) were seen in her trephine biopsy. Immunophenotyping studies showed the gated cells 
expressed CD3, CD7, CD8, CD16 and CD56 compatible with aggressive CD3+, CD56+ variant of LGL leukaemia or 
also known as LGL NK-like leukaemia. Cytogenetic analysis showed normal cells karyotype. Unfortunately specimen 
sent for TCR gene rearrangement study was unsatisfactory.
She was treated with interrupted ALL–standard risk protocol. Her disease was temporarily controlled. She had 
achieved partial clinical and haematological remission after induction. Her spleen had reduced in size and repeat bone 
marrow assessment showed presence of less than 10% of mononuclear/lymphoid cells. Subsequently, she was treated 
with another 2 courses of combination cytarabine and mitoxantrone to further control her disease. 
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ABSTRACT 
Clonal disorders of LGL may either be CD3+ CD56- or CD3- CD56+ phenotype and these have 
been designated as T-cell leukaemia (T-LGL) or natural killer cell (NK)-LGL leukaemia respectively. 
Clonality is usually demonstrated by clonal rearrangement of T-cell receptor gene rearrangement or 
identified by flowcytometry analysis. Most patients with T-LGL will have an indolent course. In this 
report we described an aggressiveness of disease in a patient with clonal CD3+ LGL leukaemia whose 
cells also co-expressed CD56 diagnosed by flowcytometry. The patient responded well to interrupt ALL 
standard risk protocol however succumbed to her disease while waiting for upfront stem cell transplant. 
This case highlights on both the classical laboratory findings of rare entity of disease as well as a review 
of the literature pertaining particularly on its management. 
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Workout for autologous peripheral blood stem cell transplant was planned. However, during an evaluation for 
allogenic haemopoietic stem cell transplantation, the patient was noted to have pancytopaenia. Subsequent BMA and 
flowcytometry studies showed she had relapsed with presence of similar types of cells. She succumbed to her illness 
fourteen months after her initial presentation.
Figure 1. BMA MGG X 400 . Circulating large mononuclear/ 
lymphoid cells, some with irregular folding nuclei, 
open chromatin and distinct nucleoli. The cytoplasm is 
abundant and some showed azurophilic granules (arrow)
Figure 2. Trephine biopsy x 400: multiple aggregates of abnormal 
lymphoid cells admixed with other haematopoietic 
elements. These cells have vesicular nuclei with open 
chromatin pattern and were positive for leukocytes 
common antigen (LCA) and CD3
DISCUSSION
Recently, CD56+ entity of haematologic malignancies has attracted attention. The WHO classification of lymphoid 
malignancies does not recognize an aggressive CD3+ CD56+ T-cell LGL as a subtype of LGL disorders [2]. However, 
several cases with similar clinicopathological and disease progression as this case have being reported worldwide. [3, 
4, 5]
We describe a rare, CD3+, CD56+ LGL leukaemia, which is a variant form of indolent T-LGL leukaemia. It is 
also described as LGL NK-like leukaemia.[4] Typically, most T-LGL leukaemia have an indolent clinical course. An 
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absolute lymphocytosis of 2-20 x109/L accompanied by neutropaenia with or without anaemia and thrombocytopaenia 
are frequent findings.[1] Clonality of LGL also has being reported in patients where the absolute lymphocytes count 
of less than 2 x 109/L.[2] Splenomegaly was the main physical finding.[3, 4] In comparison, patients with NK-cell 
leukaemia usually present with constitutional symptoms, organomegaly and leukaemic infiltration in the blood and 
bone marrow.[1] As illustrated in our case, the clinical presentation of CD3+, CD56+ aggressive variant LGL leukaemia 
was unlike the usual clinical course of T-LGL leukaemia, but remarkably similar to features of NK-cell leukaemia. 
Macon et al., documented all patients presented with advanced stage of disease, with B symptoms.[4] An absolute 
lymphocytosis (median of 4.2 x 109/L) was present in all patients at presentation which is relatively higher than values 
seen in patients with typical, indolent T-LGL leukaemia.[2, 3] The marrow, spleen, liver and extranodal involvement was 
seen in majority of cases.[3, 4, 5] Majority of patients (63%) were in a leukaemic phase at their presentation.[4]
The LGL cells are identified by their morphology and cell phenotype. Circulating leukaemic cells in aggressive 
NK-cell leukaemia sometime are indistinguishable from the normal large granular lymphocytes. As seen in this case, 
the leukaemic cells of NK-like leukaemia often exhibit marked nuclear polymorphism or have a blastic appearance.[4]
Marrow involvement is more easily established by bone marrow aspirate smears as the tissue section may only show 
subtle lymphoid infiltrates as seen in this case.[4] The common phenotype in T-LGL is CD2+, CD3+, CD4-, CD8+ 
with variable expression of CD56.[1, 2] In comparison, neoplastic cells in aggressive NK-cell leukaemia are CD2+, 
CD3-  and CD56+. Our patient’s immunophenotype analysis showed the leukaemic cells expressed CD3, CD7, CD8, 
CD16 and CD56 but were negative for intracellular MPO and intracellular CD22. These findings support the suspicion 
of a rare entity of CD3+, CD56+ variant aggressive LGL leukaemia3 also described as LGL NK-like leukaemia.[4]
A variety of cytogenetic abnormalities are much more common in NK-like leukaemia when compared to T-LGL 
leukaemia.[1] Macon et al., suggested this exercise may help to pinpoint patients with poorer prognosis as three out of 
four patients studied had an abnormal karyotype which include t(2,17), isochromosome 7q and t(8,14)[4]. Our patient’s 
cytogenetic analysis showed a normal cell karyotype.
Aggressive T-LGL leukaemia is not considered as a different entity by the latest WHO classification. Aleshkun et 
al., suggested a diagnosis of aggressive T-LGL leukaemia can be established based upon four clinical and laboratory 
features which include aggressiveness of clinical presentation (acute onset of B symptoms, hepatosplenomegaly, 
peripheral cytopaenia and lympadenopathy) together with presence of an absolute large granular lymphocytes count 
in blood film of more than 0.5 x 109/L (frequently > 10 x x109/L).[5] Phenotypically the leukaemic cells are positive for 
CD3, CD8 and CD56 as described in this case. Demonstration of clonally rearranged TCR genes of the leukkaemic 
cells also need to be established.[1, 4, 5] Unfortunately, we were unable to prove the clonality by TCR as the sample sent 
was unsuitable for processing. However, our patient does fulfill the other three clinico-laboratory features as suggested 
by Todd et al. Furthermore; TCR gene rearrangement is also a feature of indolent T-LGL leukaemia. Kojima et al., 
1995 reported a case with neither progressive nor aggressive clinical course CD3+, CD56+ LGL with TCR gene 
rearrangement.[6]
The non-progressive nature of typical T-LGL leukaemia probably is better regarded (as clonal of uncertain 
significant rather than leukaemia. Most patients usually remain asymptomatic even for more than five years.[1]
Treatment is indicated only in patients who turn aggressive and with symptomatic neutropaenia.[1, 2] In contrast, this 
CD3+, CD56+ aggressive variant LGL leukaemia needed urgent treatment as most untreated cases will die within a 
months of the diagnosis.[3, 4, 5]
Aggressive chemotherapy[4] and combination CHOP-like regimen[3, 4] have been tried but most patients die within a 
year of treatments. Gentile et al., described a case which was temporarily controlled after being treated with childhood 
ALL induction and consolidation regimen therapy. This young female was alive and awaiting for allogenic stem cell 
transplant at the time of reporting.[3] Successful haematological remission was achieved in the patient treated with 
hyper-CVAD (fractionated cylophosphamide with vincristine, adriamycin and dexamethasone) protocol alternating 
with four cycles of high-dose methotrexate and cytarabine.[5] As seen in our case, her disease was temporarily controlled 
by standard risk ALL regimen chemotherapy. She also was temporarily able to achieve clinical and haematological 
remission. Unfortunately, while waiting for stem cell transplantation, she succumbed with disease relapse less than 6 
months post chemotherapy. 
Combination chemotherapy of cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP) also have 
being used in treating this aggressive disease with variable outcome.[3, 4] Gentile et al., reported successful control 
of disease in a patient treated with CHOP followed by high dose of oral cylophosphamide.[3] This is conflicting with 
cases reported by Macon et al., where a patient died within few months of his presentation.[4] Multiple combination 
chemotherapy, aggressive chemotherapy with combination of prednisolone with other chemotherapy also failed to 
control the disease.[4] Combination of chlorumbucil and whole body irradiation have being tried to treat a patient 
who presented with generalized maculopapular rash, however this patient also succumbed one year after his 
presentation.[4]  
The prognosis of this rare and aggressive disease is poor. As described in this case, recurrence of disease may 
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occur within few months even after achieving haematological remission[5]. There is no data supporting the need of 
prophylactic intrathecal chemotherapy to control the disease. Studies also show that a long-term remission rarely 
occurs.[3, 4, 5]. Upfront autologous haematopoietic stem cell transplantation needs to be considered in managing this 
aggressive disease entity. Alekshun et al,. reported a patient who benefited by this treatment modality even after he 
had recurrence of leukaemic cells within the cerebral spinal fluid.[5] Literature search shows no data on the outcome of 
patients with aggressive NK-like leukaemia being treated with allogeneic  haematopoietic stem cell transplantion.  
CONCLUSION
Awareness among clinician and laboratory haematologists on the existence of this aggressive entity of large granular 
lymphocytic leukaemia is important in ensuring urgent and intensive treatment can be promptly initiated to control 
the disease. ALL-like induction chemotherapy protocol followed by haemopoietic stem cell transplant may rescue this 
rare disorder. 
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